Drug – bio-affecting and body treating compositions – Dentifrices
Reexamination Certificate
2002-02-15
2009-06-16
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Dentifrices
C424S401000, C424S078180, C424S078240, C424S078290, C424S078310, C424S078350, C514S772100, C514S772500, C514S772700, C514S780000, C514S781000, C514S782000, C514S901000
Reexamination Certificate
active
07547433
ABSTRACT:
Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes and/or the delivery of pharmaceutically active compounds to mucosal surfaces for topical treatment or transfer to the systemic circulation.
REFERENCES:
patent: 4615697 (1986-10-01), Robinson
patent: 4738842 (1988-04-01), Dow et al.
patent: 4851393 (1989-07-01), Rha et al.
patent: 5081158 (1992-01-01), Pomerantz
patent: 5403578 (1995-04-01), Gordon
patent: 5458879 (1995-10-01), Singh et al.
patent: 5462749 (1995-10-01), Rencher
patent: 5474768 (1995-12-01), Robinson
patent: 5543150 (1996-08-01), Bologna et al.
patent: 5667492 (1997-09-01), Bologna et al.
patent: 5900230 (1999-05-01), Cutler
patent: 5968500 (1999-10-01), Robinson
patent: 5989535 (1999-11-01), Nayak
patent: 6017521 (2000-01-01), Robinson et al.
patent: 6056950 (2000-05-01), Saettone et al.
patent: 6071959 (2000-06-01), Rhodes et al.
patent: 6103266 (2000-08-01), Tapolsky et al.
patent: 6166044 (2000-12-01), Sandborn et al.
patent: 6375963 (2002-04-01), Repka et al.
patent: 6632423 (2003-10-01), Jafari et al.
patent: 2002/0076421 (2002-06-01), Dobrozsi
patent: 2002/0103219 (2002-08-01), Jacob
patent: 2002/0142042 (2002-10-01), Mumper et al.
patent: 2003/0060486 (2003-03-01), Jacob et al.
patent: 2003/0098438 (2003-05-01), Haslin
patent: 2005/0281862 (2005-12-01), Karakelle et al.
patent: 07565664 (1997-02-01), None
patent: 0765664 (1997-04-01), None
patent: 0765664 (1997-04-01), None
patent: 1593097 (1981-07-01), None
patent: 1593097 (1981-07-01), None
patent: 285761 (1997-05-01), None
patent: 282537 (1998-09-01), None
patent: 6071959 (2000-06-01), None
patent: 6103266 (2000-08-01), None
patent: 6166044 (2000-12-01), None
patent: 96/09829 (1996-04-01), None
patent: 9609829 (1996-04-01), None
patent: 9609829 (1996-04-01), None
patent: 9801112 (1998-01-01), None
patent: 9801112 (1998-01-01), None
patent: 99/63986 (1999-12-01), None
patent: 9963986 (1999-12-01), None
patent: 00/50078 (2000-08-01), None
patent: 0050078 (2000-08-01), None
patent: 02/09637 (2002-02-01), None
patent: 0209637 (2002-02-01), None
DeCordi, D, Martina, S, “Gelclair: potentially an efficacious treat for chemotherapy-induced mucositis”, 2001, 10-12.
Innocenti, M. Moscatelli, G, Lopez, S, “Efficacy of Gelclair in Reducing Pain in Patients with Oral Lesions-Preliminary Findings from an Open Pilot Study”, 2001.
Berndtson, J., “A Preliminary Study of Orassist (Gelclair) in the management of Oral Mucositis”, 2001, 17-21, Svensk Sjukhustandlak artidning.
Editio Cantor Verlag, “Rote Liste 2000”, 1-5,7,9,12-16,18,19,21, Rote ListeService Aulendorf XP002203083.
Dr. Marcello Innocenti, Clinical Evaluation of Gelcair Concentrated Oral Gel, a new option for treating painful oral conditions, pp. 1-4, Milan, Italy, (2001).
PDR 21 Edition 2000, Physicians Desk Reference for Nonprescription Drugs and Dietary Supplements, pp. 640 and 787.
Dr. Heddie Sedano, Oral Complications During Cancer Treatment, Jun. 13, 2002, pp. 1-5.
Jelka Korbar-Smid et al, An Oxtetracycline Formulation to be Applied at the Oral Mucosa, Aug. 5, 1975, pp. 271-276, University of Ljubljana.
Dixon J, Search Conducted on Hyaluronic Acid and Mucositis, May 29, 2002, pp. all, US.
Kaken Seiyaku KK, Abstract, JP 59186913, Apr. 4, 1983.
Tsumura & Co, Abstract JP 8291083, Apr. 17, 1995.
Cheng, K.K.F. et al. “Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients”Eur. J. Cancer(Nov. 2001) 37(16):2056-63.
Demarosi, F. et al. “Prevention and Treatment of Chemo- and Radiotherapy-Induced Oral Mucosistis”Minerva Stomatol. (May, 2002) 51(5):173-186.
Dodd, M.J. et al. “Risk Factors for Chemotherapy-Induced Oral Mucositis: Dental Appliances, Oral Hygiene, Previous Oral Lesions, and History of Smoking”Cancer Invest.(1999) 17(4):278-284.
Epstein, J.B. and A.W. Chow “Oral Complications Associated with Immunosuppression and Cancer Therapies”Infectious Disease Clinics of North America(Dec. 1999) 13(4):901-923.
Fulton, J.S. et al. “Management of Oral Complications”Semin. Oncol. Nurs.(Feb. 2002) 18(1):28-35.
Ghate, J.V. and J.L. Jorizzo “Behçet's Disease and Complex Aphthosis”J. Am. Acad. Dermatol.(Jan. 1999) 40(1):1-18.
Miles, D.A. and M.M. Howard “Disorders Affecting the Oral Cavity: Diagnosis and Management of Oral Lichen Planus”Dermatologic Clinics(Apr. 1996) 14(2):281-290.
Morales, A. et al. “Treatment of Refractory Interstitial Cystitis”Int. Urogynecol. J.(1996) 7(4):215-220.
Plevová, P. “Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review”Oral Oncology(Sept. 1999) 35:453-470.
Popovsky, J.L. and C. Camisa “New and Emerging Therapies for Diseases of the Oral Cavity”Dermatologic Clinics(Jan. 2000) 18(1):113-125.
Sonis, S.T. et al. “Validation of a New Scoring System for the Assessment of Clinical Trial Research of Oral Mucositis Induced by Radiation or Chemotherapy”Cancer(May 15, 1999) 85(10):2103-2113.
Sonis, S.T. et al. “Oral Complications of Cancer Therapy”Oncology(May 2002) 16(5):680-686, 691-692, 695.
Worthington, H.V. et al. “Interventions for treating oral mucositis for patients with cancer receiving treatment”Cochrane Database Syst. Rev.(2002) 1:CD001973, located at http://web19.epnet.com/citation.asp?rds=1&sxp=32&...%5B0+%2Dproximity+op.
International Search Report for PCT/US02/04577 dated Jun. 21, 2002.
Written Opinion for PCT/US02/04577 dated Sep. 16, 2003.
International Preliminary Examination Report for PCT/US02/04577 dated Jan. 12, 2004.
Buhse et al. (2005) “Topical drug classification,”International Journal of Pharmaceutics295:101-112.
Khandwala et al. (1997) “5% Amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. Clinical demonstration of acceleration of healing and resolution of pain,”Oral Surg Oral Med Oral Pathol Oral Radiol Endod83(2):222-230.
Rote Liste Service (Editor), “Rote Liste 2000”, Edition Cantor Verlag, Aulendorf XP002203083.
Loher, F., International Search Report, dated Jun. 21, 2002, Europe.
Baud Christiane M.
Jacob Jeremy E.
Nowotnik David P.
Access Pharmaceuticals Inc.
Foley & Lardner LLP
Knoski, Esq. Antoinette F.
Krass Frederick
Packard Benjamin
LandOfFree
Liquid formulations for the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liquid formulations for the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liquid formulations for the prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144887